Projekt S01

Axel Walch and Mirko Peitzsch Project S01
Axel Walch and Mirko Peitzsch


Dr. rer. nat. Mirko Peitzsch

Mirko.Peitzsch[at]uniklinikum-dresden.de
Institute for Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden

Prof. Dr. Axel Walch

Axel.Walch[at]helmholtz-muenchen.de
Research Unit Analytical Pathology, Helmholtz Zentrum München

Dr. med. Martin Bildingmaier

Martin.Bidlingmaier[at]med.uni-münchen.de
Endokrinologisches Labor, Medizinische Klinik und Poliklinik IV,
Klinikum der Universität München

Dr. rer. nat. Max Kurlbaum

Kurlbaum_m1[at]ukw.de
Medizinische Klinik und Poliklinik I,
Endokrinologie und Diabetologie,
Zentraleinheit Klinische Massenspektrometrie (ZKMS), Universitätsklinikum Würzburg,

Dr. Tiago C. Alves (PhD)
Tiago.Alves[at]uniklinikum-dresden.de
Institute for Clinical Chemistry and Laboratory Medicine,
University Hospital Carl Gustav Carus Dresden,
Technische Universität Dresden

Scientific staff:

Na Sun – Postdoc

Technical staff:

Dennis Fröbel – Technician

Project Description

Project S01 provides centralized highly sophisticated analytical tools, which are crucial in the context of adrenal research due to the need of accurate measurements of adrenal hormones, such as catecholamine metabolites and steroids. Besides liquid chromatography – tandem mass spectrometry (LC-MS/MS) based methodologies for targeted quantitative metabolite profiling and untargeted metabolomics, further screening platforms using high-resolution mass spectrometry, such as MALDI-mass spectrometry imaging in the context of tissue-based research, for biomarker discovery etc., are available. All those mass spectrometry based methodologies provide a powerful tool to uncover changes in metabolism associated with adrenal diseases.

Analytical platform – Specific Aims

(I) Provide state-of-the-art analytical methods for sensitive and targeted analyses of different panels of compounds including flux analysis and untargeted metabolomics/steroidomics approaches.

(II) Improve and develop methodologies for targeted quantitative LC-MS/MS analysis and untargeted metabolomics.

(III) Harmonise methods with other institutions and translate precise and accurate research-based analytical tools into routine clinical applications.

Publications:

N. Sun, Y. Wu, K. Nanba, S. Sbiera, S. Kircher, T. Kunzke, M. Aichler, S. Berezowska, J. Reibetanz, W. E. Rainey, M. Fassnacht, A. Walch, M. Kroiss, Endocrinology 2018.

C. Urban, A. Buck, J. T. Siveke, F. Lordick, B. Luber, A. Walch, M. Aichler, Biochim Biophys Acta 2018, 1862, 51-60.
M. Aichler, T. Kunzke, A. Buck, N. Sun, M. Ackermann, D. Jonigk, A. Gaumann, A. Walch, Lab Invest 2018, 98, 141-149.

S. Richter, …, M. Peitzsch, …, M. Kroiss, F Beuschlein, …, J Lenders, G Eisenhofer, B. Klink. Metabolome-guided genomics to identify mutations in isocitrate dehydrogenase, fumarate hydratase and succinate dehydrogenase genes in pheochromocytoma and paraganglioma, Genetics in Medicine 2018, in press.

Erlic Z*, Kurlbaum M*, Deutschbein T, Nolting S, Prejbisz A, Timmers H, Richter S, Prehn C, Weismann D, Adamski J, Januszewicz A, Reincke M, Fassnacht M, Robledo M, Eisenhofer G, Beuschlein F, Kroiss M. Metabolic impact of pheochromocytoma/paraganglioma: targeted metabolomics in patients before and after tumor removal. Eur J Endocrinol 2019; 181:647-657(*,equal contribution)

Kroiss M, Megerle F, Kurlbaum M, Zimmermann S, Wendler J, Jimenez C, Lapa C, Quinkler M, Scherf-Clavel O, Habra MA, Fassnacht M. Objective Response and Prolonged Disease Control of Advanced Adrenocortical Carcinoma with Cabozantinib. J Clin Endocrinol Metab 2020; 105